drugset / Trial / NCT06024031

NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy

NCT06024031

Phase 2 Active not recruiting 30 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-arm clinical study to evaluate the role of NAC after chemotherapy among patients with AML can promote hematopoietic recovery and does not affect the remission rate of the leukemia.

Timeline

Start
2023-09-10
Primary completion
2024-09-01
Completion
2025-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 400 mg Oral